Introduction {#s1}
============

Aortic stenosis (AS) is the most common valve disease affecting elderly patients, occurring in \~3.4% of the population over 75 years of age ([@B1]). Transcatheter aortic valve implantation (TAVI) has transformed the management of AS patients and is considered to be the standard of care in elderly patients at excessive-, high- and intermediate-surgical risk. Indeed, TAVI has surpassed surgical aortic valve replacement (SAVR) as the dominant strategy for the treatment of symptomatic severe AS ([@B2]). National and regional differences in the availability of TAVI have emerged however and there exist considerable variations in the use of TAVI or SAVR ([@B3]).

Societal guidelines suggest that a Heart Team approach should facilitate the determination of the most appropriate therapeutic strategy for AS patients ([@B4], [@B5]). Such patients are usually referred to a dedicated Structural Heart clinic in a TAVI center for consideration of the most appropriate treatment. A proportion of patients with severe AS referred for TAVI are however likely to be more appropriately treated with SAVR due to young age and low operative risk, anatomical challenges, or concomitant coronary artery or mitral valve disease ([@B4]). Similarly, some patients at extreme-operative risk may be more appropriately treated conservatively. There is however, little information available on the final treatment allocation of patients referred to dedicated TAVI clinics ([@B6], [@B7]). Such information may have implications for healthcare resource allocation, service development planning, assessment of equitable patient access, and physician training.

We sought to address this knowledge gap by examining the disposition of patients referred to a dedicated TAVI clinic in contemporary clinical practice, to understand the motives for the chosen treatment allocation, and to describe clinical outcomes of various treatment strategies.

Methods {#s2}
=======

Patient Population
------------------

In this prospective single center study, data was collected on all patients with severe AS referred for assessment to a dedicated out-patient TAVI clinic between February 2014 and August 2017. Patients were referred from community medical practitioners, the general medical service, cardiologists, and cardiothoracic surgeons. The diagnosis of severe AS was reassessed in the clinic and patients with \< severe AS were excluded from the study. Demographic, clinical, laboratory, echocardiographic, and procedural data were prospectively collected into a dedicated database. All patients provided informed consent for the procedure and the hospital ethical committee approved the data collection for this study.

Patients were categorized according to treatment allocation: TAVI, SAVR, or optimal medical therapy (OMT). The TAVI and SAVR groups included patients undergoing the respective intervention or those that died awaiting the procedure. The OMT group included patients treated with standard heart failure therapies, and balloon aortic valvuloplasty, but not deemed suitable for TAVI.

Endpoints and Definitions
-------------------------

In all cases, treatment allocation and the rationale for this allocation was documented after Heart Team discussion. Echocardiographic data was defined according to established criteria ([@B8]). Severe AS was defined according to standard societal guidelines (mean pressure gradient \>40 mmHg, aortic valve area by continuity equation \< 1 cm^2^). In cases of suspected low-flow low-gradient AS, the diagnosis was confirmed using dobutamine stress echocardiography and/or multislice computed tomography. Severe pulmonary hypertension was defined as pulmonary artery systolic pressure ≥60 mmHg. Chronic kidney disease was defined as estimated glomerular filtration rate \<30 mL/min/1.73 m^2^, chronic obstructive pulmonary disease as the ratio of forced expiratory volume in one second (FEV1) over forced vital capacity (FVC)--(FEV1/FVC) ≤70%. Obstructive coronary artery disease was defined as visual stenosis of a major epicardial artery ≥70% diameter stenosis.

Surgical risk was calculated using the Society of Thoracic Surgeons predicted risk of mortality (STS-PROM) score and the European System for Cardiac Operative Risk Evaluation (EuroSCORE; logistic EuroSCORE; and EuroSCORE II).

Clinical endpoints included procedural mortality, 30-day mortality, 6-month all-cause mortality, and stroke/transient ischemic attack as well as procedural complications. All outcomes were adjudicated according to the updated VARC-2 criteria ([@B9]). Clinical follow-up was performed by patient attendance at out-patient clinic or telephonic interview with patients, family members, and general practitioners. Follow-up time was the time between the procedure and follow-up in patients undergoing TAVI and SAVR or as the time from treatment decision in patients managed with OMT.

Statistical Analysis
--------------------

Continuous variables are presented as mean and standard deviation or median with interquartile range according to distribution. Normally distributed variables were compared with the Student *t*-test and non-normally distributed variables compared with the Wilcoxon rank-sum test. Categorical variables are presented as numbers and percentages, and were compared using chi-square or Fisher exact test. Multiple comparisons were analyzed using analysis of variance with Bonferroni correction or with the Kruskal-Wallis test. Survival was depicted using Kaplan-Meier graphs. Due to significant differences in baseline characteristics between treatment groups, we do not present comparative statistics on clinical outcomes. A probability value \<0.05 was considered to indicate statistical significance. All analyses were performed with Minitab software version 17.

Results {#s3}
=======

Patients and Treatment Allocation
---------------------------------

A total of 245 patients with AS were referred for assessment during the study period ([Figure 1](#F1){ref-type="fig"}). Moderate AS was determined in 32 (13.1%) cases after careful multimodal imaging assessment. Among 213 patients with severe AS, 31.1% (*N* = 32) did not have symptoms, thus yielding a final study population of 181 patients with severe symptomatic AS. The median age of the study cohort was 83 \[IQR 79--87\] years and 53% (*N* = 96) were male ([Table 1](#T1){ref-type="table"}).

![Patients flow. Values are number (%). AS, aortic stenosis; TAVI, transcatheter aortic valve implantation; SAVR, surgical aortic valve replacement; OMT, optimal medical therapy.](fcvm-06-00188-g0001){#F1}

###### 

Baseline characteristics according to treatment allocation.

  **Demographic characteristics**                       **All (*N =* 181)**   **TAVI (*N* = 132)**   **SAVR (*N* = 18)**   **OMT (*N* = 31)**   ***p*-value**
  ----------------------------------------------------- --------------------- ---------------------- --------------------- -------------------- ------------------------------------------------------------------------------------------------------------
  Age, median \[IQR\]                                   83 \[79--87\]         83.3 \[80.5--87\]      73 \[60--79\]         86 \[82--88\]        \<0.001[^\*^](#TN1){ref-type="table-fn"}[^\#^](#TN2){ref-type="table-fn"}[^\$^](#TN3){ref-type="table-fn"}
  Male sex                                              96 (53)               67 (50.8)              12 (66.7)             17 (54.8)            0.4
  **Symptoms**                                                                                                                                  
     NYHA Class III/IV                                  137 (77.8)            107 (84.3)             12 (66.7)             19 (61.3)            0.01[^\*^](#TN1){ref-type="table-fn"}
     Angina                                             42 (24.4)             35 (28)                4 (22.2)              3 (9.7)              0.1
     Syncope                                            50 (28.4)             42 (33.1)              2 (11.1)              6 (19.4)             0.1
  **Co-morbid conditions**                                                                                                                      
     Diabetes mellitus                                  40 (22.3)             29 (22.3)              5 (27.8)              6 (19.3)             0.8
     Hypertension                                       147 (81.2)            116 (87.9)             10 (55.6)             21 (67.7)            \<0.001[^\*^](#TN1){ref-type="table-fn"}[^\#^](#TN2){ref-type="table-fn"}
     CKD eGFR \<30 mL/min/1.73 m^2^                     24 (13.9)             20 (15.6)              1(5.9)                3 (11.1)             0.4
     COPD                                               26 (14.5)             23 (17.7)              1 (5.6)               2 (6.5)              0.1
     PVD                                                29 (16.2)             28 (21.5)              0 (0)                 1 (3.2)              0.001[^\*^](#TN1){ref-type="table-fn"}[^\#^](#TN2){ref-type="table-fn"}
     Stroke                                             34 (19)               27 (20.8)              2 (11.1)              5 (16.1)             0.5
     Prior MI                                           49 (27.7)             37 (28.7)              4 (22.2)              8 (26.7)             0.8
     Prior PCI                                          55 (30.9)             42 (32.6)              4 (22.2)              9 (29)               0.6
     Prior CABG                                         25 (14)               21 (16.2)              1 (5.6)               3 (10)               0.3
     Atrial fibrillation                                72 (39.8)             50 (38.2)              9 (50)                13 (41.9)            0.6
     PASP \> 60 mmHg                                    8 (4.5)               5 (3.9)                0 (0)                 3 (9.7)              --
     Permanent pacemaker                                21 (11.8)             15 (11.5)              0 (0)                 6 (20)               0.1
  **Biological assessment**                                                                                                                     
     Weight, Kg                                         74.9 ± 16.4           74.7 ± 16              83.4 ± 17.2           70.3 ± 16.7          0.1
     eGFR, mL/min/1.73 m^2^                             51 \[39--64.5\]       50 \[38.3--64\]        77 \[43--86.5\]       51 \[38--59\]        0.02[^\#^](#TN2){ref-type="table-fn"}[^\$^](#TN3){ref-type="table-fn"}
  **Pre TAVI Coronary angiography,**                                                                                                            
     Obstructive CAD (\>70% visual diameter stenosis)   57 (33.7)             41 (32.5)              5 (27.8)              11 (44)              0.8
     PCI                                                20 (13.8)             23 (22.1)              0 (0)                 7 (30.4)             0.01[^\#^](#TN2){ref-type="table-fn"}[^\$^](#TN3){ref-type="table-fn"}
  **Echocardiography**                                                                                                                          
     Peak gradient, mmHg                                75 \[65--90\]         75 \[66--90\]          70 \[59--78.5\]       72 \[60--101\]       N/A
     Mean gradient, mmHg                                47.5 \[39--57\]       48 \[40--57.5\]        41 \[36--49.1\]       48 \[37.3--63.5\]    N/A
     AVA, cm^2^                                         0.7 \[0.5--0.8\]      0.6 \[0.5--0.8\]       0.7 \[0.5--1.1\]      0.7 \[0.6--0.8\]     N/A
     LVEF, %                                            55 \[50--60\]         55 \[50--60\]          60 \[55--60\]         55 \[40--60\]        N/A
     PASP, mmHg                                         35 \[28--45\]         34 \[28--41\]          37 \[25.8--47\]       40 \[33.5--49.5\]    N/A
     MR Grade ≥ 3                                       32 (18.1)             29 (22.5)              2 (11.1)              1 (3.3)              N/A
  **Surgical risk**                                                                                                                             
     EuroSCORE II                                       8.1 ± 8.5             9.2 ± 9.2              2.6 ± 1.6             6.4 ± 6.1            0.004[^\#^](#TN2){ref-type="table-fn"}[^\$^](#TN3){ref-type="table-fn"}
     Logistic EuroSCORE                                 20.3 ± 15.3           22.9 ± 15.9            6.2 ± 3.7             17.8 ± 11.5          \<0.001[^\#^](#TN2){ref-type="table-fn"}[^\$^](#TN3){ref-type="table-fn"}
     STS PROM score                                     5.4 ± 4.6             6.1 ± 4.9              2.2 ± 1.3             4.5 ± 2.4            0.001[^\*^](#TN1){ref-type="table-fn"}[^\#^](#TN2){ref-type="table-fn"}[^\$^](#TN3){ref-type="table-fn"}

*Values are number (%), median \[interquartile range\], or mean ± SD. p \< 0.05 was used as the level of statistical significance*.

*Denotes statistical significance in TAVI-OMT pairwise comparison*.

*Denotes statistical significance in TAVI-SAVR pairwise comparison*.

*Denotes statistical significance in SAVR-OMT pairwise comparison. COPD, chronic obstructive pulmonary disease; PVD, peripheral vascular disease; MI, myocardial infarction; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; PASP, pulmonary artery systolic pressure; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; CAD, coronary artery disease; AVA, aortic valve area; MR, mitral regurgitation; LVEF, left ventricular ejection fraction; STS, Society of Thoracic Surgeons Predicted Risk of Mortality score*.

Treatment allocation after Heart Team discussion was as follows ([Table 1](#T1){ref-type="table"}): TAVI in 132 (53.9%); SAVR in 18 (9.9%); and OMT in 31 (17.1%). One patient initially managed with OMT proceeded to TAVI as a novel large THV (Medtronic, 34 mm Evolut R) became commercially available. Two patients died awaiting TAVI. Surgery was preferred to TAVI in 18 patients (7.3%) due to low surgical risk (*N* = 11; 61.1%)--mean STS score: 2.2%; excessive annulus size for commercially available TAVI devices at the time (*N* = 5; 27.8%); and bicuspid aortic valve morphology with aortic root dilatation (*N* = 2; 11.1%).

OMT was preferred in 31 cases (12.7%) due to a patient preference to avoid intervention (*N* = 12; 38.7%); excessive annulus size but too frail for surgery (*N* = 4; 12.9%); severe frailty or immobility (*N* = 5; 16.1%); end-stage pulmonary disease (*N* = 3; 9.7%); severe cognitive impairment (*N* = 2; 6.5%); and end-stage malignancy (*N* = 1; 3.2%). In 4 cases (12.9%), patients died before completion of their out-patient TAVI work-up. One patient (3.2%) did not attend follow-up ([Table 2](#T2){ref-type="table"}).

###### 

Indication for treatment allocation to surgery or medical therapy.

  **Treatment allocation**                           ***N* (%)**
  -------------------------------------------------- ----------------------
  Primary reason for OMT                             ***N*** **=** **31**
  Patient preference                                 12 (38.7)
  Excessive annulus size but too frail for surgery   4 (12.9)
  Severe cognitive impairment                        2 (6.5)
  End-stage malignancy                               1 (3.2)
  End-stage pulmonary disease                        3 (9.7)
  Severe frailty / immobility                        5 (16.1)
  Did not attend clinic                              1 (3.2)
  Died before work-up complete                       4 (12.9)
  Primary reason for SAVR                            ***N*** **=** **18**
  Low surgical risk                                  11 (61.1)
  Excessive annulus size                             5 (27.8)
  Aortic root dilatation                             2 (11.1)

*Values are number (%). OMT, optimal medical therapy; SAVR, surgical aortic valve replacement*.

Demographic Information
-----------------------

Baseline demographic, clinical, biological and echocardiographic characteristics according to treatment allocation are presented in [Table 1](#T1){ref-type="table"}. Patients managed with SAVR were significantly younger than those in either the OMT or TAVI cohorts (73 \[IQR 60--79\] vs. 86 \[IQR 82--88\] and 83.3 \[IQR 80.5--87\], respectively; *P* \< 0.001). As expected, SAVR patients had lower STS scores then the other groups (2.2 ± 1.3% vs. 4.5 ± 2.4% and 6.1 ± 4.9% respectively; *P* = 0.001). Patients undergoing SAVR also had higher median left ventricular ejection fraction than those in the OMT or the TAVI group \[60% \[IQR 55--60\] vs. 55% \[IQR 40--60\] and 55% (50--60), respectively\]. The median waiting time for TAVI was 70 \[23--160\] days, whereas median waiting time for SAVR was 272 \[181--361\] days (*P* \< 0.001).

Clinical Outcome
----------------

Clinical outcomes are presented in [Table 3](#T3){ref-type="table"}. SAVR was associated with numerically higher rates of bleeding (27.8% vs. 10.6%) and acute kidney injury (33.3% vs. 4.5%), than TAVI, but with lower rates of new permanent pacemaker insertion (11.1% vs. 28.9%) and vascular complications (0% vs. 9.1%).

###### 

Procedural and clinical outcomes.

  --------------------------------------------------------------------------------------------------------
  **Outcomes, *N* (%)**              **All**\          **TAVI**\         **SAVR**\        **OMT**\
                                     **(*N* = 181)**   **(*N* = 132)**   **(*N* = 18)**   **(*N* = 31)**
  ---------------------------------- ----------------- ----------------- ---------------- ----------------
  Procedural mortality (*N* = 150)   2 (1.3)           1 (0.8)           1 (5.6)          N/A

  30-day mortality                   6 (3.3)           3 (2.3)           2 (11.1)         1 (3.2)

  6 month all-cause morality         21 (11.8)         12 (9.3)          3 (16.7)         6 (19.4)

  Stroke/TIA                         6 (3.6)           3 (2.5)           1 (5.6)          2 (7.1)

  **Procedural complications**                                                            

   Myocardial Infarction             1 (0.7)           0 (0)             1 (5.6)          N/A

   Any bleeding                      19 (12.7)         14 (10.6)         5 (27.8)         N/A

   Life-threatening bleeding         8 (5.3)           5 (3.8)           3 (16.7)         N/A

   Acute kidney injury               12 (8)            6 (4.5)           6 (33.3)         N/A

   Any vascular complication         12 (8)            12 (9.1)          0 (0)            N/A

   Major vascular complication       6 (4)             6 (4.5)           0 (0)            N/A

   New permanent pacemaker           27 (18)           25 (18.9)         2 (11.1)         N/A
  --------------------------------------------------------------------------------------------------------

*Values are number (%). TAVI, transcatheter aortic valve implantation; SAVR, surgical aortic valve replacement; OMT, optimal medical therapy; TIA, transient ischaemic attack*.

When compared to TAVI, SAVR was associated with a numerically higher procedural (5.6% vs. 0.8%) and 30-day mortality (11.1% vs. 2.3%). Six-month follow-up data was available for all patients in the OMT and SAVR group, and for 129 (97.7%) patients in the TAVI cohort. Median follow-up was 14 months \[IQR 7--22\] in the OMT cohort, 16.5 months \[IQR 7.5--27\] in the SAVR group and 12 months \[IQR 8--21.8\] for TAVI patients. Six-month all-cause mortality was highest among patients managed with OMT as compared to SAVR or TAVI (19.4% vs. 16.7% vs. 9.3%, respectively). All-cause mortality is displayed using Kaplan-Meier survival curves in [Figure 2](#F2){ref-type="fig"}.

![All cause mortality at 12 months. TAVI, trancatheter aortic valve implantation (*N* = 131); OMT, optimal medical therapy (*N* = 30); SAVR, sugical aortic valve replacement (*N* = 18).](fcvm-06-00188-g0002){#F2}

Discussion {#s4}
==========

The main findings of our study are that only 53.5% of patients referred to a dedicated clinic for consideration for TAVI went on to receive a transcatheter heart valve. After reassessment of the severity of AS, 13.1% were reclassified as moderate rather than severe AS and among severe AS patients, up to 13.1% were asymptomatic and did not proceed to intervention. Among symptomatic severe AS patients, 20% were unsuitable for TAVI, with 7.3% undergoing SAVR and a further 12.7% of cases were deemed futile and hence managed with OMT. This information has important implications.

It seems striking that in contemporary clinical practice, only one in two patients referred for TAVI actually receive this life-saving therapy. These results are however not unique, and other studies have documented similarly low rates of application of TAVI technology: 59% in an Italian study (*N* = 98) and 39% in a Canadian report ([@B6], [@B7]). These results must be contextualized however: when patients with moderate or asymptomatic AS were excluded, then nearly three-quarters (73%) were treated with TAVI. Further 10% were referred for SAVR.

In our study, more than 1 in 10 (13.1%) patients purportedly with severe AS were reclassified as moderate AS after assessment at a dedicated clinic. These data suggest that societal guidelines and position papers which recommend centralization of complex procedures, such as TAVI, at dedicated tertiary referral centers are appropriate ([@B4], [@B10], [@B11]). Centralization serves, not only to improve procedural outcome, but also more appropriately select the most appropriate intervention (if any) for a given patient. In AS, ancillary diagnostic capabilities such as transoesophageal and dobutamine stress echocardiography, and multislice computed tomography are required. Such techniques may not be readily available in smaller referring centers and could result in patients being misclassified, as demonstrated in our study.

There remain few data describing the prevalence of symptoms in elderly patients with severe AS referred for TAVI ([@B6], [@B7]). In our patient population, quality of life and functional capacity are often more important patient-related outcome measures than mortality ([@B12], [@B13]). Indeed, elderly patients are often reluctant to undertake procedures that confer a mortality advantage if symptomatic benefit is not guaranteed. In the current study, 13.1% of our elderly patients (mean age 84.7 years) with severe AS did not report cardiovascular symptoms. In selected cases, exercise stress testing was performed to confirm the absence of symptoms, but in many cases, additional testing was not performed as the patients were satisfied with their quality of life. Such treatment decisions are appropriate in this elderly population but are less relevant in younger AS patients where the mortality advantage of TAVI is more pertinent.

In patients treated with OMT (*N* = 31), 12 (38.7%) refused the procedure, 4 (12.9%) died before the decision was finalized and 4 (12.9%) did not proceed because of unsuitable anatomy (large annuli) and concomitant frailty. In all other cases, the procedure was deemed futile due to co-morbidities such as end-stage malignancy, excessive frailty, and cognitive impairment. These results are similar to previous studies in which the majority of patients who did not proceed to TAVI either declined the procedure, had unsuitable anatomy for percutaneous approach, or due to significant co-morbidities a symptomatic improvement was viewed as unlikely ([@B6], [@B7]). Patients managed with OMT in our cohort were older than patients in the two other subgroups, but interestingly, the prevalence of co-morbidities was not higher than in patients treated with TAVI or SAVR. The STS score of patients managed with OMT was significantly lower, than the mean STS score in the TAVI cohort (4.5 ± 2.4 vs. 6.1 ± 4.9 respectively; *P* = 0.04). As expected, patients referred for SAVR had the lowest STS score (2.2 ± 1.3; *P* \< 0.001). The lower STS score in the OMT group compared to those undergoing TAVI may be attributed to factors that are not accounted for in the traditional surgical risk scores, such as frailty, cognitive impairment, etc. These treatment decisions highlight the important role of a multidisciplinary team (Heart Team) in determining management strategies. Moreover, these data point to the vital importance of considering patient\'s preference in decision making; nearly 4 in 10 patients treated with OMT refused TAVI. As expected, the prognosis in the OMT group was dismal with all-cause mortality of 19.4% at 6 months.

Despite TAVI now being extended to younger and lower risk populations, almost 1 in 10 patients (*N* = 18; 9.9%) in the current cohort were referred for SAVR. The recent publication of two low risk TAVI randomized trials will change these practices and will result in many younger patients being referred for TAVI in the coming years ([@B14], [@B15]). In our study, surgery was preferential in many cases, irrespective of operative risk, due to the presence of bicuspid aortic valve and dilation of the aortic root or concomitant severe coronary artery disease. Surgery will remain an important treatment option for patients with infective endocarditis, aortic thrombus or other anatomic characteristics that render TAVI unsuitable, or those with coexisting multivalve disease amenable to surgical correction ([@B4]). In contrast, the 28% of severe AS patients referred for SAVR due to excessively large aortic annuli not suitable for commercially available TAVI systems at that time would be expected to have TAVI in contemporary practice since larger devices such as the Medtronic Evolut R 34 mm (Medtronic, Minneapolis, Minnesota, USA) or overexpansion of the SAPIEN 3 (Edwards Lifesciences, Irvine, CA, USA) prosthesis have emerged.

In a significant proportion of patients, frailty and cognitive impairment may limit the symptomatic benefit derived from TAVI ([@B16], [@B17]). Intervention in such patients is deemed to be "futile." It is important to acknowledge however, that in many such cases, a delayed presentation or diagnosis may have contributed to patients being labeled as futile. Opportunistic screening for severe valvular heart disease by general practitioners in the community has the potential to reduce the number of patients presenting late and improve outcome ([@B18]). A heart valve disease awareness survey performed among patients above the age of 60 years in nine European countries, found that only 7% of patients could identify symptoms of AS correctly and in 54.2% of cases, their general practitioner did not routinely use a stethoscope to examine their heart ([@B19]). It is recommended that all patients age ≥70 years should undergo opportunistic cardiovascular examination for a systolic murmur, symptoms of AS, and a referral for a transthoracic echocardiography if a murmur is detected ([@B20]). Community events, such as European Heart Valve Disease Awareness day serve to raise awareness of AS among general population and encourage seeking medical advice at an earlier stage ([@B21]).

Limitations {#s5}
===========

The current study comprises a single center experience of a small number of patients. Furthermore, changes in the threshold for intervention have evolved during the study enrolment which would have affected the disposition of patients at intermediate risk. Indeed, recent data suggesting extension of TAVI to patients at low operative risk will further impact patient disposition in the future. Consideration will need to be given to valve durability and the risk of paravalvular leak especially in this younger, lower risk cohort. Advancements in TAVI technology and patient screening, and local awareness of the dedicated TAVI clinic are also likely to have impacted the proportion of patients assigned to TAVI or OMT.

Our main objective was to report the ultimate treatment allocation for this patient population. Nevertheless, we also provide clinical outcome data according to the VARC definitions, but we did not present statistical comparisons between treatment groups due to considerable differences in the baseline characteristics of these patient populations. Interpretation of outcome data should be interpreted with caution, since the sample size is small and selection bias was introduced in the screening process.

Conclusions {#s6}
===========

Almost half of all patients with severe AS referred to a dedicated clinic for TAVI do not receive a transcatheter heart valve. A considerable proportion of these elderly patients are reclassified as moderate AS, are asymptomatic, or intervention is determined to be futile due to advanced frailty or cognitive impairment. Early detection and increased awareness of valvular heart disease are required to reduce the proportion of patients declined TAVI.
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